Evidence map›Paper›PMID 33852625›Full record

ArticlePloS one2021

Koala cathelicidin PhciCath5 has antimicrobial activity, including against Chlamydia pecorum.

Emma Peel, Yuanyuan Cheng, Julianne T Djordjevic, Denis O'Meally, Mark Thomas, Michael Kuhn, Tania C Sorrell, Wilhelmina M Huston, Katherine Belov

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Current status and future directions ofFrontiers in veterinary science · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Emma PeelSchool of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales, Australia.
Yuanyuan ChengSchool of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales, Australia.
Julianne T DjordjevicCentre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.ORCID 0000-0003-4207-4115
Denis O'MeallyCenter for Gene Therapy, Beckman Research Institute of the City of Hope, Duarte, California, United States of America.
Mark ThomasSchool of Life Sciences, University of Technology Sydney, Sydney, New South Wales, Australia.
Michael KuhnZoetis, Veterinary Medicine Research and Development, Kalamazoo, Michigan, United States of America.
Tania C SorrellCentre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Wilhelmina M HustonSchool of Life Sciences, University of Technology Sydney, Sydney, New South Wales, Australia.
Katherine BelovSchool of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-9762-5554
The University of Sydney · AUUniversity of Technology Sydney · AUCity of Hope · USZoetis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Devastating fires in Australia over 2019-20 decimated native fauna and flora, including koalas. The resulting population bottleneck, combined with significant loss of habitat, increases the vulnerability of remaining koala populations to threats which include disease. Chlamydia is one disease which causes significant morbidity and mortality in koalas. The predominant pathogenic species, Chlamydia pecorum, causes severe ocular, urogenital and reproductive tract disease. In marsupials, including the koala, gene expansions of an antimicrobial peptide family known as cathelicidins have enabled protection of immunologically naïve pouch young during early development. We propose that koala cathelicidins are active against Chlamydia and other bacteria and fungi. Here we describe ten koala cathelicidins, five of which contained full length coding sequences that were widely expressed in tissues throughout the body. Focusing on these five, we investigate their antimicrobial activity against two koala C. pecorum isolates from distinct serovars; MarsBar and IPTaLE, as well as other bacteria and fungi. One cathelicidin, PhciCath5, inactivated C. pecorum IPTaLE and MarsBar elementary bodies and significantly reduced the number of inclusions compared to the control (p<0.0001). Despite evidence of cathelicidin expression within tissues known to be infected by Chlamydia, natural PhciCath5 concentrations may be inadequate in vivo to prevent or control C. pecorum infections in koalas. PhciCath5 also displayed antimicrobial activity against fungi and Gram negative and positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Electrostatic interactions likely drive PhciCath5 adherence to the pathogen cell membrane, followed by membrane permeabilisation leading to cell death. Activity against E. coli was reduced in the presence of 10% serum and 20% whole blood. Future modification of the PhciCath5 peptide to enhance activity, including in the presence of serum/blood, may provide a novel solution to Chlamydia infection in koalas and other species.

Indexed as

AnimalsAnti-Infective AgentsAntimicrobial Cationic PeptidesAustraliaCathelicidinsChlamydiaChlamydia InfectionsEscherichia coliMarsupialiaMethicillin-Resistant Staphylococcus aureusPhascolarctidaeAnti-Infective AgentsAntimicrobial Cationic PeptidesCathelicidins

Identifiers

PMID33852625
PMCPMC8046226
OpenAlexW3154695885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.